Novel targeted therapies and vaccination strategies for mesothelioma

Current Treatment Options in Oncology

Volumn 12, Issue 2, 2011, Pages 149-162

  Bagia, Mamta ^a,b   Nowak, Anna K ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMATUXIMAB; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CP 870893; DASATINIB; DENDRITIC CELL VACCINE; DEPSIPEPTIDE; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; LEXATUMUMAB; MAPATUMUMAB; OBATOCLAX; PEMETREXED; PLATINUM; RANPIRNASE; RAPAMYCIN; ROMIDEPSIN; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VATALANIB; VORINOSTAT;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CARCINOGENESIS; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VACCINATION;

EID: 79958053931     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0149-1     Document Type: Article

References (47)

1. NJ Vogelzang JJ Rusthoven J Symanowski, et al. 2003 Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2636 44 12860938 10.1200/JCO.2003.11.136 1:CAS:528:DC%2BD2cXptlCktL4%3D (Pubitemid 46606305)
2. SV Ivanov J Miller R Lucito, et al. 2009 Genomic events associated with progression of pleural malignant mesothelioma Int J Cancer 124 589 99 18973227 10.1002/ijc.23949 1:CAS:528:DC%2BD1MXmt1GhtQ%3D%3D Describes the genomic changes in mesothelioma
3. L Strizzi A Catalano G Vianale, et al. 2001 Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma J Pathol 193 468 75 11276005 10.1002/path.824 1:CAS:528:DC%2BD3MXivVGrsbw%3D (Pubitemid 32266815)
4. Y Ohta V Shridhar RK Bright, et al. 1999 VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours Br J Cancer 81 54 61 10487612 10.1038/sj.bjc.6690650 1:CAS:528:DyaK1MXmt12htr0%3D (Pubitemid 29415491)
5. F Demirag E Unsal A Yilmaz A Caglar 2005 Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma Chest 128 3382 7 16304288 10.1378/chest.128.5. 3382 1:CAS:528:DC%2BD2MXhtlSis7jI (Pubitemid 41698667)
6. T Karrison HL Kindler DR Gandara, et al. 2007 Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) J Clin Oncol 25 7526 Abstr
7. J Dowell R Taub C Lan, et al. 2009 A multicenter phase II study of pemetrexed (P), cisplatin (C), and bevacizumab (B) in patients (pts) with advanced malignant mesothelioma (MM) J Clin Oncol 27 15s 7578 abstr
8. DM Jackman HL Kindler BY Yeap, et al. 2008 Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma Cancer 113 808 14 18543326 10.1002/cncr.23617 1:CAS:528:DC%2BD1cXhtVGhsbnE
9. TM Jahan L Gu X Wang, et al. 2006 Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the cancer and leukemia group B (CALGB 30107) J Clin Oncol 24 7081 Abstr
10. LL Garland K Chansky AJ Wozniak, et al. 2010 SWOG S0509: a phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma J Clin Oncol 27 7511 Abstr
11. HI Pass GJ Brewer R Dick, et al. 2008 A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results Ann Thorac Surg 86 383 9 18640301 10.1016/j.athoracsur.2008.03.016 (Pubitemid 351978017)
12. G Chong J Desai DC Bibby, et al. 2010 A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation J Clin Oncol 28 3054 10.1200/JCO.2009.25.7121 abstr
13. H Dazzi PS Hasleton N Thatcher, et al. 1990 Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody Br J Cancer 61 924 6 2372497 10.1038/bjc.1990.207 1:STN:280:DyaK3czitFynsA%3D%3D (Pubitemid 20197007)
14. A Destro GL Ceresoli M Falleni, et al. 2006 EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations Lung Cancer 51 207 15 16384623 10.1016/j.lungcan.2005.10.016 1:STN:280:DC%2BD28%2FlvFCktQ%3D%3D (Pubitemid 43144364)
15. F Roberts CM Harper I Downie RA Burnett 2001 Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of 13 antibodies Am J Clin Pathol 116 253 62 11488073 10.1309/XL6K-8E62-9FLD-V8Q8 1:STN:280:DC%2BD3Mvkt1Omtg%3D%3D (Pubitemid 33044331)
16. AW Langerak CA van der Linden-van Beurden MA Versnel 1996 Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines Biochim Biophys Acta 1305 63 70 8605252 (Pubitemid 26051947)
17. PA Janne XF Wang L Krug, et al. 2007 Sorafenib in malignant mesothelioma (MM): a phase II trial of the cancer and leukemia Group B (CALGB 30307) J Clin Oncol 25 7707 10.1200/JCO.2007.11.1336 Abstr (Pubitemid 47477271)
18. AK Nowak M Millward RJ Francis, et al. 2010 Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM) J Clin Oncol 28 7036 Abstr
19. R Jagadeeswaran PC Ma TY Seiwert, et al. 2006 Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma Cancer Res 66 352 61 16397249 10.1158/0008-5472.CAN-04-4567 1:CAS:528: DC%2BD28XhsFWnug%3D%3D (Pubitemid 43166042)
20. ME Ramos-Nino SR Blumen T Sabo-Attwood, et al. 2008 HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway Am J Respir Cell Mol Biol 38 209 17 17872495 10.1165/rcmb.2007-0206OC 1:CAS:528:DC%2BD1cXhsVags74%3D (Pubitemid 351162843)
21. W Liu E Bodle JY Chen, et al. 2001 Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines Am J Respir Cell Mol Biol 25 111 8 11472983 1:CAS:528:DC%2BD3MXlvFSntLw%3D (Pubitemid 32682713)
22. LL Belyanskaya TM Marti S Hopkins-Donaldson, et al. 2007 Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin Mol Cancer 6 66 17953743 10.1186/1476-4598-6-66 (Pubitemid 350278695)
23. Y Soini V Kinnula R Kaarteenaho-Wiik, et al. 1999 Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma Clin Cancer Res 5 3508 15 10589765 1:CAS:528: DyaK1MXotV2gsbg%3D
24. J Li J Viallet EB Haura 2008 A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells Cancer Chemother Pharmacol 61 525 34 17505826 10.1007/s00280-007-0499-3 1:CAS:528:DC%2BD1cXisl2ks7k%3D (Pubitemid 350275989)
25. J Adams 2004 The proteasome: a suitable antineoplastic target Nat Rev Cancer 4 349 60 15122206 10.1038/nrc1361 1:CAS:528:DC%2BD2cXjsFSlu7k%3D (Pubitemid 38579481)
26. GJ Gordon M Mani G Maulik, et al. 2008 Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma Cancer Chemother Pharmacol 61 549 58 17522864 10.1007/s00280-007-0500-1 1:CAS:528:DC%2BD1cXjsFWrsQ%3D%3D
27. LM Krug T Curley L Schwartz, et al. 2006 Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid Clin Lung Cancer 7 257 61 16512979 10.3816/CLC.2006.n.003 (Pubitemid 43280028)
28. DA Altomare H You GH Xiao, et al. 2005 Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth Oncogene 24 6080 9 15897870 10.1038/sj.onc.1208744 1:CAS:528:DC%2BD2MXpvFert7g%3D (Pubitemid 43080058)
29. SM Wilson D Barbone T-M Yang, et al. 2008 mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids Am J Respir Cell Mol Biol 39 576 83 18511708 10.1165/rcmb.2007-0460OC 1:CAS:528:DC%2BD1cXhtlGltrvP
30. M-L Hartman JM Esposito BY Yeap DJ Sugarbaker 2010 Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma J Thorac Cardiovasc Surg 139 1233 40 19853261 10.1016/j.jtcvs.2009.06.027 1:CAS:528:DC%2BC3cXltF2htrw%3D
31. M Anraku KS Cunningham Z Yun, et al. 2008 Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma J Thorac Cardiovasc Surg 135 823 9 18374762 10.1016/j.jtcvs.2007.10.026 (Pubitemid 351417931)
32. JPJJ Hegmans A Hemmes H Hammad, et al. 2006 Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses Eur Respir J 27 1086 95 16540497 10.1183/09031936.06.00135305 1:CAS:528: DC%2BD28XlvF2hsb0%3D (Pubitemid 44914290)
33. M Lucchi A Chella F Melfi, et al. 2007 Four-modality therapy in malignant pleural mesothelioma: a phase II study J Thorac Oncol 2 237 42 17410047 10.1097/JTO.0b013e318031d05c (Pubitemid 47181329)
34. M Lucchi A Picchi G Ali, et al. 2010 Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? Interact Cardiovasc Thorac Surg 10 572 6 20053697 10.1510/icvts.2009.223255
35. JP Hegmans JD Veltman ME Lambers, et al. 2010 Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma Am J Respir Crit Care Med 181 1383 90 20167848 10.1164/rccm.200909-1465OC 1:CAS:528:DC%2BC3cXpsFSrsbk%3D
36. AK Nowak RA Lake AL Marzo, et al. 2003 Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells J Immunol 170 4905 13 12734333 1:CAS:528:DC%2BD3sXjsVGqsro%3D (Pubitemid 36554719)
37. A Powell J Creaney S Broomfield, et al. 2006 Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma Lung Cancer 52 189 97 16563560 10.1016/j.lungcan.2006.01.007
38. LM Krug T Dao AB Brown, et al. 2010 WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer Cancer Immunol Immunother 59 1467 79 20532500 10.1007/s00262-010- 0871-8 1:CAS:528:DC%2BC3cXpt12lsLw%3D
39. BW Robinson J Creaney R Lake, et al. 2003 Mesothelin-family proteins and diagnosis of mesothelioma Lancet 362 1612 6 14630441 10.1016/S0140-6736(03) 14794-0 1:CAS:528:DC%2BD3sXovF2rsrk%3D (Pubitemid 37443528)
40. R Hassan S Bullock A Premkumar, et al. 2007 Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers Clin Cancer Res 13 5144 9 17785569 10.1158/1078-0432.CCR-07-0869 1:CAS:528:DC%2BD2sXpvFGqsrY%3D (Pubitemid 47502082)
41. RJ Kreitman R Hassan DJ Fitzgerald I Pastan 2009 Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P Clin Cancer Res 15 5274 9 19671873 10.1158/1078-0432.CCR-09-0062 1:CAS:528:DC%2BD1MXpvFeitLY%3D
42. R Hassan W Ebel EL Routhier, et al. 2007 Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin Cancer Immun 7 20 18088084
43. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363:711-23
44. S Kim G Buchlis ZG Fridlender, et al. 2008 Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy Cancer Res 68 10247 56 19074893 10.1158/0008-5472.CAN-08-1494 1:CAS:528:DC%2BD1cXhsV2itL7L
45. RA Lake BW Robinson 2005 Immunotherapy and chemotherapy-a practical partnership Nat Rev Cancer 5 397 405 15864281 10.1038/nrc1613 1:CAS:528:DC%2BD2MXjslertbk%3D (Pubitemid 40637831)
46. AK Nowak S Mahendran R van der Most RA Lake 2008 Cisplatin and pemetrexed synergises with immunotherapy to result in cures in established murine malignant mesothelioma Proc Am Assoc Cancer Res 2073 2487
47. AK Nowak BW Robinson RA Lake 2003 Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 4490 6 12907622 1:CAS:528:DC%2BD3sXmtFersrY%3D (Pubitemid 36951021)